Genflow Biosciences plc (LON: GENF), the first pure-play longevity biotechnology firm to list in Europe, raised capital through a £3.7 million oversubscribed placing and the company’s admission to the standard segment of the main market of the London Stock Exchange.
Genflow is a UK-based biotechnology company focused on the science of longevity and the development of gene therapies, through novel therapeutics, to counteract the effects of ageing and diseases associated with advanced age.
The company is led, and was founded, by Dr Eric Leire, who has two decades of experience in cell and gene therapy and has led several therapy companies, including Enochian Biosciences which is listed on the Nasdaq. Dr Leire has brought together experts in various fields within the longevity sector to establish a strong scientific advisory board which will guide Genflow’s pre-clinical and clinical programmes and provide external perspectives to steer its research and development strategies.
The Hill Dickinson team was led by Corporate partner Jaspal Sekhon (Picture) with assistance from Victor Oliynik (associate, Corporate), Oliver Hart (paralegal, Corporate), Jamie Foster (partner, Health and Life Sciences), Caroline Lorkin (associate, Health and Life Sciences) and Will Steed (senior associate, Employment).
Law Firms: Hill Dickinson;
Clients: Genflow Biosciences plc;